Cell adhesion is a key determinant in de Novo multidrug resistance (MDR): New targets for the prevention of acquired MDR

Molecular Cancer Therapeutics

Volumn 1, Issue 1, 2001, Pages 69-78

  Shain, Kenneth H ^a   Dalton, William S ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ANIMAL; APOPTOSIS; CELL ADHESION; DRUG RESISTANCE; HUMAN; MULTIDRUG RESISTANCE; NEOPLASM; PHYSIOLOGY; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL ADHESION; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS;

EID: 0035502588     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. Barut, B., Chauhan, D., Uchiyama, H., and Anderson, K. C. Interleukin-6 functions as an intracellular growth factor in hairy cell leukemia in vitro. J. Clin. Investig., 92: 2346-2352, 1993. (Pubitemid 23333541)
2. Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernandez-Luna, J. L., Nunez, G., Dalton, W. S., and Jove, R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity, 10: 105-115, 1999. (Pubitemid 29077388)
3. Lichtenstein, A., Berenson, J., Norman, D., Chang, M. P., and Carlile, A. Production of cytokines by bone marrow cells obtained from patients with multiple myeloma. Blood, 74: 1266-1273, 1989. (Pubitemid 19227434)
4. Klein, B. Cytokines, cytokine receptors, transduction signals, and oncogenes in human multiple myeloma. Semin. Hematol., 32: 4-19, 1995. (Pubitemid 24370132)
5. 1 integrin prevents apoptosis in B cell chronic lymphocytic leukemia: correlation with Bcl-2 and Bax. Leukemia (Baltimore), 13: 266-274, 1999.
6. 5 subunit in HT29 colon carcinoma cells suppresses apoptosis triggered by serum deprivation. Exp. Cell Res., 224: 208-213, 1996.
7. Sutherland, R. M., and Durand, R. E. Cell contact as a possible contribution to radiation resistance of some tumours. Br. J. Radiol., 45: 788-789, 1972.
8. Kip1on resistance of tumor cells to anticancer agents. Nat. Med., 2: 1204-1210, 1996.
9. Schuetz, J. D., and Schuetz, E. G. Extracellular matrix regulation of multidrug resistance in primary monolayer cultures of adult rat hepatocytes. Cell Growth Differ., 4: 31-40, 1993. (Pubitemid 23262851)
10. Hoyt, D. G., Rusnak, J. M., Mannix, R. J., Modzelewski, R. A., Johnson, C. S., and Lazo, J. S. Integrin activation suppresses etoposide-induced DNA strand breakage in cultured murine tumor-derived endothelial cells. Cancer Res., 56: 4146-4149, 1996. (Pubitemid 26305007)
11. Damiano, J. S., Cress, A. E., Hazlehurst, L. A., Shtil, A. A., and Dalton, W. S. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood, 93: 1658-1667, 1999. (Pubitemid 29102494)
12. Sethi, T., Rintoul, R. C., Moore, S. M., MacKinnon, A. C., Salter, D., Choo, C., Chilvers, E. R., Dransfield, I., Donnelly, S. C., Strieter, R., and Haslett, C. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat. Med., 5: 662-668, 1999. (Pubitemid 29289430)
13. Damiano, J. S., and Dalton, W. S. Integrin-mediated drug resistance in multiple myeloma. Leuk. Lymphoma, 38: 71-81, 2000. (Pubitemid 30224324)
14. Damiano, J. S., Hazlehurst, L. A., and Dalton, W. S. Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and γ-irradiation. Leukemia (Baltimore), 15: 1232-1239, 2001. (Pubitemid 32776447)
15. kip1levels and contributes to cell adhesion mediated drug resistance (CAMDR). Oncogene, 19: 4319-4327, 2000.
16. 1 intergrin-mediated adhesion correlates with drug resistance in U937 leukemia cells. Blood, 98: 1897-1903, 2001.
17. Oloumi, A., MacPhail, S. H., Johnston, P. J., Banath, J. P., and Olive, P. L. Changes in subcellular distribution of topoisomerase IIα correlate with etoposide resistance in multicell spheroids and xenograft tumors. Cancer Res., 60: 5747-5753, 2000.
18. Tan, B., Piwnica-Worms, D., and Ratner, L. Multidrug resistance transporters and modulation. Curr. Opin. Oncol., 12: 450-458, 2000. (Pubitemid 32268882)
19. Persidis, A. Cancer multidrug resistance. Nat. Biotechnol., 17: 94-95, 1999. (Pubitemid 29037219)
20. Dalton, W. S. Mechanisms of drug resistance in hematologic malignancies. Semin. Hematol., 34: 3-8, 1997. (Pubitemid 28032414)
21. Kellner, U., Rudolph, P., and Parwaresch, R. Human DNA-topoisomerases: diagnostic and therapeutic implications for cancer. Onkologie, 23: 424-430, 2000.
22. Dalton, W. S., Durie, B. G. M., Alberts, D. S., Gerlach, J. H., and Cress, A. E. Characterization of a new drug resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res., 46: 5125-5130, 1986. (Pubitemid 16008277)
23. Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M., and Deeley, R. G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science (Wash. DC), 258: 1650-1654, 1992. (Pubitemid 23012438)
24. Meredith, J. E., Jr., Fazeli, B., and Schwartz, M. A. The extracellular matrix as a cell survival factor. Mol. Biol. Cell, 4: 953-961, 1993. (Pubitemid 23309430)
25. Dalton, W. S. Alternative (non-P-glycoprotein) mechanisms of drug resistance in non-Hodgkin's lymphoma. Hematol. Oncol. Clin. N. Am., 11: 975-986, 1997. (Pubitemid 27431157)
26. Dalton, W. S., and Scheper R. J. Lung-resistance protein: determining its role in multidrug resistance. J. Natl. Cancer Inst. (Bethesda), 91: 1604-1605, 1999. (Pubitemid 29479928)
27. Austin C. A., and Marsh, K. L. Eukaryotic DNA topoisomerase IIβ. 20: 215-226, 1998.
28. Friche, E., Danks, M. K., Schmidt, C. A., and Beck, W. T. Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells. Cancer Res., 51: 4213-4218, 1991.
29. Valkov, N. I., and Sullivan, D. M. Drug resistance to DNA topoisomerase I and II inhibitors in human leukemia, lymphoma, and multiple myeloma. Semin. Hematol., 34: 48-62, 1997. (Pubitemid 28032420)
30. Pegg, A. E. Repair of O6-alkylguanine by alkyltransferases. Mutat. Res., 462: 83-100, 2000.
31. 6-alkylguanine-DNA alkyltransferase activity in human colon cancer. Clin. Cancer Res., 1: 519-525, 1995.
32. Eischen, C. M., Kottke, T. J., Martins, L. M., Basi, G. S., Tung, J. S., Earnshaw, W. C., Leibson, P. J., and Kaufmann, S. H. Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood, 90: 935-943, 1997. (Pubitemid 27314125)
33. Landowski, T. H., Shain, K. H., Oshiro, M. M., Buyuksal, I., Painter, J. S., and Dalton, W. S. Myeloma cells selected for resistance to CD95-mediated apoptosis are not cross-resistant to cytotoxic drugs: evidence for independent mechanisms of caspase activation. Blood, 94: 265-274, 1999. (Pubitemid 29300158)
34. Shain, K. H., Landowski, T. H., Buyuksal, I., Cantor, A. B., and Dalton, W. S. Clonal variability in CD95 expression is the major determinant in Fas-mediated but not chemotherapy-mediated apoptosis in the RPMI 8226 multiple myeloma cell line. Leukemia (Baltimore), 14: 830-840, 2000. (Pubitemid 30235060)
35. Friesen, C., Herr, I., Krammer, P. H., and Debatin, K-M. Involvement of the CD95 (APO-1/fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med., 2: 574-577, 1996. (Pubitemid 26150685)
36. Fulda, S., Susin, S. A., Kroemer, G., and Debatin, K. M. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. Cancer Res., 58: 4453-4460, 1998. (Pubitemid 28450051)
37. Antoku, K., Liu, Z., and Johnson, D. E. Inhibition of caspase proteases by CrmA enhances the resistance of human leukemic cells to multiple chemotherapeutic agents. Leukemia (Baltimore), 11: 1665-1672, 1997. (Pubitemid 27458605)
38. Schurmann, A., Mooney, A. F., Sanders, L. C., Sells, M. A., Wang, H. G., Reed, J. C., and Bokoch, G. M. p21-activated kinase 1 phosphorylates the death agonist bad and protects cells from apoptosis. Mol. Cell. Biol., 20: 453-461, 2000. (Pubitemid 30023086)
39. Minn, A. J., Rudin, C. M., Boise, L. H., and Thompson, C. B. Expression of Bcl-xL can confer a multidrug resistance phenotype. Blood, 86: 1903-1910, 1995.
40. Zhang, Y., Fujita, N., and Tsuruo, T. p21Waf1/Cip1 acts in synergy with bcl-2 to confer multidrug resistance in a camptothecin-selected human lung-cancer cell line. Int. J. Cancer, 83: 790-797, 1999.
41. Nuessler, V., Stotzer, O., Gullis, E., Pelka-Fleischer, R., Pogrebniak, A., Gieseler, F., and Wilmanns, W. Bcl-2, bax and bcl-xL expression in human sensitive and resistant leukemia cell lines. Leukemia (Baltimore), 13: 1864-1872, 1999. (Pubitemid 29535273)
42. Kaufmann, S. H. Cell death induced by topoisomerase-targeted drugs: more questions than answers. Biochim. Biophys. Acta, 1400: 195-211, 1998. (Pubitemid 28475104)
43. Dorr, R., Karanes, C., Spier, C., Grogan, T., Greer, J., Moore, J., Weinberger, B., Schiller, G., Pearce, T., Litchman, M., Dalton, W., Roe, D., and List, A. F. Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia. J. Clin. Oncol., 19: 1589-1599, 2001. (Pubitemid 32230858)
44. Futscher, B. W., Foley, N. E., Gleason-Guzman, M. C., Meltzer, P. S., Sullivan, D. M., and Dalton, W. S. Verapamil suppresses the emergence of P-glycoprotein-mediated multi-drug resistance. Int. J. Cancer, 66: 520-525, 1996. (Pubitemid 26176770)
45. Abbaszadegan, M. R., Foley, N. E., Gleason-Guzman, M. C., and Dalton, W. S. Resistance to the chemosensitizer verapamil in a multi-drug-resistant (MDR) human multiple myeloma cell line. Int. J. Cancer, 66: 506-514, 1996. (Pubitemid 26178173)
46. Abbaszadegan, M. R., Cress, A. E., Futscher, B. W., Bellamy, W. T., and Dalton, W. S. Evidence for cytoplasmic P-glycoprotein location associated with increased multidrug resistance and resistance to chemosensitizers. Cancer Res., 56: 5435-5442, 1996. (Pubitemid 27011377)
47. Taylor, C. W., Dalton, W. S., Parrish, P. R., Gleason, M. C., Bellamy, W. T., Thompson, F. H., Roe, D. J., and Trent, J. M. Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line. Br. J. Cancer, 63: 923-929, 1991.
48. List, A. F. Preclinical investigations of drug resistance. Curr. Opin. Oncol., 7: 19-27, 1995.
49. Teicher, B. A., Herman, T. S., Holden, S. A., Wang, Y. Y., Pfeffer, M. R., Crawford, J. W., and Frei, E., III. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science (Wash. DC), 247: 1457-1461, 1990.
50. Frisch, S. M., and Francis, H. Disruption of epithelial cell-matrix interactions induces apoptosis. J. Cell Biol., 124: 619-626, 1994. (Pubitemid 24064472)
51. Walker, A., Taylor, S. T., Hickman, J. A., and Dive, C. Germinal center-derived signals act with Bcl-2 to decrease apoptosis and increase clonogenicity of drug-treated human B lymphoma cells. Cancer Res., 57: 1939-1945, 1997. (Pubitemid 27209725)
52. Anwar, A. R., Moqbel, R., Walsh, G. M., Kay, A. B., and Wardlaw, A. J. Adhesion to fibronectin prolongs eosinophil survival. J. Exp. Med., 177: 839-843, 1993. (Pubitemid 23104295)
53. 1 integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression. Proc. Natl. Acad. Sci. USA, 92: 6161-6165, 1995.
54. Shain, K. H., Landowski, T. H., and Dalton, W. S. The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistance. Curr. Opin. Oncol., 12: 557-563, 2000. (Pubitemid 32039655)
55. Parise, L. V., Lee, J., and Juliano, R. L. New aspects of integrin signaling in cancer. Semin. Cancer Biol., 10: 407-414, 2000. (Pubitemid 32181911)
56. Kumar, C. C. Signaling by integrin receptors. Oncogene, 17: 1365-1373, 1998.
57. Tamura, T., Aoyama, N., Saya, H., Haga, H., Futami, S., Miyamoto, M., Koh, T., Ariyasu, T., Tachi, M., Kasuga, M., and Takahashi, R. Induction of Fas-mediated apoptosis in p53-transfected human colon carcinoma cells. Oncogene, 11: 1939-1946, 1995.
58. Giancotti, F. G. Integrin signaling: specificity and control of cell survival and cell cycle progression. Curr. Opin. Cell Biol., 9: 691-700, 1997. (Pubitemid 27424926)
59. Clark, E. A., and Brugge, J. S. Integrins and signal transduction pathways: the road taken. Science (Wash. DC), 268: 233-239, 1995.
60. Clark, E. A., King, W. G., Brugge, J. S., Symons, M., and Hynes, R. O. Integrin-mediated signals regulated by members of the rho family of GTPases. J. Cell Biol., 142: 573-586, 1998. (Pubitemid 28361561)
61. Zhang, Z., Vuori, K., Wang, H., Reed, J. C., and Ruoslahti, E. Integrin activation by R-ras. Cell, 85: 61-69, 1996. (Pubitemid 26116807)
62. O'Toole, T. E., Ylanne, J., and Culley, B. M. Regulation of integrin affinity states through an NPXY motif in the β subunit cytoplasmic domain. J. Biol. Chem., 270: 8553-8558, 1995.
63. Hughes, P. E., Renshaw, M. W., Pfaff, M., Forsyth, J., Keivens, V. M., Schwartz, M. A., and Ginsberg, M. H. Suppression of integrin activation: a novel function of a Ras/Raf-initiated MAP kinase pathway. Cell, 88: 521-530, 1997. (Pubitemid 27154417)
64. 1 integrin activation by Ha-Ras and R-Ras. J. Biol. Chem., 275: 22590-22596, 2000.
65. Liu, Z. J., Tanaka, Y., Fujimoto, H., Mine, S., Morinobu, A., Yagita, H., Okumura, K., Oishi, I., Udagawa, J., Yamamura, H., and Minami, Y. A novel role for H-Ras in the regulation of very late antigen-4 integrin and VCAM-1 via c-Myc-dependent and -independent mechanisms. J. Immunol., 163: 4901-4908, 1999. (Pubitemid 29501255)
66. Keely, P. J., Rusyn, E. V., Cox, A. D., and Parise, L. V. R-Ras signals through specific integrin α cytoplasmic domains to promote migration and invasion of breast epithelial cells. J. Cell Biol., 145: 1077-1088, 1999. (Pubitemid 29270064)
67. Katagiri, K., Hattori, M., Minato, N., Irie, S., Takatsu, K., and Kinashi, T. Rap1 is a potent activation signal for leukocyte function-associated antigen 1 distinct from protein kinase C and phosphatidylinositol-3-OH kinase. Mol. Cell. Biol., 20: 1956-1969, 2000. (Pubitemid 30123812)
68. Tsukamoto, N., Hattori, M., Yang, H., Bos, J. L., and Minato, N. Rap1 GTPase-activating protein SPA-1 negatively regulates cell adhesion. J. Biol. Chem., 274: 18463-18469, 1999.
69. St. Croix, B., Sheehan, C., Rak, J. W., Florenes, V. A., Slingerland, J. M., and Kerbel, R. S. E-cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27KIP1. J. Cell Biol., 142: 557-571, 1998. (Pubitemid 28361560)
70. Kip1induces drug resistance by preventing apoptosis upstream of cytochrome c release and procaspase-3 activation in leukemic cells. Oncogene, 18: 1411-1418, 1999.
71. Kip1mediates its antiapoptotic activity. Oncogene, 18: 4839-4847, 1999.
72. Desagher, S., and Martinou, J. C. Mitochondria as the central control point of apoptosis. Trends Cell Biol., 10: 369-377, 2000. (Pubitemid 30612469)
73. Tu, Y., Renner, S., Xu, F., Fleishman, A., Taylor, J., Weisz, J., Vescio, R., Rettig, M., Berenson, J., Krajewski, S., Reed, J. C., and Lichtenstein, A. Bcl-X expression in multiple myeloma: possible indicator of chemoresistance. Cancer Res., 58: 256-262, 1998. (Pubitemid 28047064)
74. Kluck, R. M., Bossy-Wetzel, E., Green, D. R., and Newmeyer, D. D. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science (Wash. DC), 275: 1132-1136, 1997. (Pubitemid 27097313)
75. Gilmore, A. P., Metcalfe, A. D., Romer, L. H., and Streuli, C. H. Integrin-mediated survival signals regulate the apoptotic function of Bax through its conformation and subcellular localization. J. Cell Biol., 149: 431-446, 2000.
76. Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., and Greenberg, M. E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell, 91: 231-241, 1997. (Pubitemid 27456390)
77. Harada, H., Becknell, B., Wilm, M., Mann, M., Huang, L. J., Taylor, S. S., Scott, J. D., and Korsmeyer, S. J. Phosphorylation and inactivation of BAD by mitochondria-anchored protein kinase A. Mol. Cell, 3: 413-422, 1999. (Pubitemid 29292598)
78. Datta, S. R., Katsov, A., Hu, L., Petros, A., Fesik, S. W., Yaffe, M. B., and Greenberg, M. E. 14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation. Mol. Cell, 6: 41-51, 2000.
79. Folkman, J., and Moscona, A. Role of cell shape in growth control. Nature (Lond.), 273: 345-349, 1978. (Pubitemid 8344174)
80. Chen, C. S., Mrksich, M., Huang, S., Whitesides, G. M., and Ingber, D. E. Geometric control of cell life and death. Science (Wash. DC), 276: 1425-1428, 1997. (Pubitemid 27235413)
81. Pennington, M. E., Lam, K. S., and Cress, A. E. The use of a combinatorial library method to isolate human tumor cell adhesion peptides. Mol. Divers., 2: 19-28, 1996. (Pubitemid 126817061)
82. DeRoock, I. B., Pennington, M. E., Sroka, T. C., Lam, K. S., Bowden, G. T., Bair, E. L., and Cress, A. E. Synthetic peptides inhibit adhesion of human tumor cells to extracellular matrix proteins. Cancer Res., 61: 3308-3313, 2001. (Pubitemid 32695018)
83. Wang, J. C. DNA topoisomerases. Annu. Rev. Biochem., 54: 665-697, 1985. (Pubitemid 15073661)
84. Sebti, S. M., and Hamilton, A. D. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene, 19: 6584-6593, 2000. (Pubitemid 32197696)
85. Eskens, F. A., Stoter, G., and Verweij, J. Farnesyl transferase inhibitors: current developments and future perspectives. Cancer Treat. Rev., 26: 319-332, 2000.
86. Liu, L., Moesner, P., Kovach, N. L., Bailey, R., Hamilton, A. D., Sebti, S. M., and Harlan, J. M. Integrin-dependent leukocyte adhesion involves geranylgeranylated protein(s). J. Biol. Chem., 274: 33334-33340, 1999. (Pubitemid 129511635)
87. Fisher, J. E., Rogers, M. J., Halasy, J. M., Luckman, S. P., Hughes, D. E., Masarachia, P. J., Wesolowski, G., Russell, R. G., Rodan, G. A., and Reszka, A. A. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc. Natl. Acad. Sci. USA, 96: 133-138, 1999. (Pubitemid 29036065)
88. Luckman, S. P., Hughes, D. E., Coxon, F. P., Graham, R., Russell, G., and Rogers, M. J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res., 13: 581-589, 1998. (Pubitemid 28163009)
89. Rogers, M. J., Gordon, S., Benford, H. L., Coxon, F. P., Luckman, S. P., Monkkonen, J., and Frith, J. C. Cellular and molecular mechanisms of action of bisphosphonates. Cancer (Phila.), 88: 2961-2978, 2000. (Pubitemid 30413179)
90. Fuks, Z., Vlodavsky, I., Andreef, M., McLoughlin, M., and Haimovitz-Friedman, A. Effects of extracellular matrix on the response of endothelial cells to radiation in vitro. Eur. J. Cancer, 28: 725-731, 1992.